Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 3: 545 - 553

DOI: https://doi.org/10.19852/j.cnki.jtcm.20240308.004

Original articles

Clinical efficacy and gene chip expression analysis of Shenzhu Guanxin recipe granules (参术冠心方颗粒) in patients with intermediate coronary lesions

  • Xiao JIN ,
  • Bingxin WU ,
  • Miaoyang LIN ,
  • Biying ZHONG ,
  • Luoqi LIN ,
  • Danping XU
Expand
  • 1 Department of Traditional Chinese Medicine, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, China
    2 Department of Cardiology, Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China
    3 Department of Traditional Chinese Medicine, the Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, China

Received date: 2022-10-22

  Accepted date: 2023-02-10

  Online published: 2024-03-08

Supported by

Traditional Chinese Medicine Bureau of Guangdong Province: Research on the Mechanism of Shen Shu Guan Xin Fang in Reducing Hypoxia Induced Myocardial Cell Injury by Regulating miR-24(20221108);Science and Technology Projects in Guangzhou: Exploring the Intervention of Shenzhu Guanxin Formula on Myocardial Ischemia Based on MiR-24 Mediated Bim/Caspase Apoptosis Signal Pathway Mechanism Research(202201010521);Science and Technology Innovation Projects of Shenzhen: to Study the Mechanism of Hesperidin in Improving Heart Failure Based on Myocardial Inflammation Mediated by MtDNA-sGAS-STING Signaling Pathway(JCYJ20220530144212026);Futian Healthcare Research Project: To Study the Anti-atherosclerosis Effects and Mechanism of Shenzhu Guanxin Decoction on Inhibiting Platelet-mediated Inflammation Based on the Theory of "Phlegm-stasis Interjunction"(FTWS2022012)

Fold

Abstract

OBJECTIVE: To evaluate the clinical efficacy and safety of Shenzhu Guanxin recipe granules (参术冠心颗粒, SGR) in treating patients with intermediate coronary lesions (ICL), and to investigate the potential mechanism though a transcriptome sequencing approach.

METHODS: ICL patients with Qi deficiency and phlegm stasis were adopted and randomly assigned to a case group or a control by random number generator in a 1:1 randomization ratio to evaluate the clinical efficacy.

RESULTS: There was no significant difference between the two groups in coronary computed tomography angiography related indexes in the two groups before and after intervention. Through the gene chip expression analysis, it is finally concluded that there are 355 differential mRNAs (190 up-regulated genes and 165 down regulated genes) when compared the SGR group and placebo group. Through protein-protein interaction network analysis of differentially expressed genes, 10 hub genes were finally obtained: CACNA2D2, CACNA2D3, DNAJC6, FGF12, SGSM2, CACNA1G, LRP6, KIF25, OXTR, UPB1.

CONCLUSIONS: SGR combined with Western Medicine can be safely used to treat ICL patients with Qi deficiency and phlegm stasis. The possible mechanism of action and relevant gene loci and pathway were proposed.

Key words： intermediate coronary lesions; gene expression profiling; Qi deficiency and phlegm stasis; Shenzhu Guanxin recipe granules

Cite this article

Xiao JIN , Bingxin WU , Miaoyang LIN , Biying ZHONG , Luoqi LIN , Danping XU . Clinical efficacy and gene chip expression analysis of Shenzhu Guanxin recipe granules (参术冠心方颗粒) in patients with intermediate coronary lesions[J]. Journal of Traditional Chinese Medicine, 2024 , 44(3) : 545 -553 . DOI: 10.19852/j.cnki.jtcm.20240308.004

References

1. Collaborators GCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736-88.
2. Pencina MJ, Navar AM, Wojdyla D, et al. Quantifying importance of major risk factors for coronary heart disease. Circulation 2019; 139: 1603-11.
3. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 2019; 234: 16812-23.
4. Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol 2007; 49 : 839-48.
5. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 : 87-165.
6. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213-60.
7. Yang X, He T, Han S, et al. The Role of Traditional Chinese Medicine in the regulation of oxidative stress in treating coronary heart disease. Oxid Med Cell Longev 2019; 2019: 3231424.
8. Zhang KJ, Zheng Q, Zhu PC, et al. Traditional Chinese Medicine for coronary heart disease: clinical evidence and possible mechanisms. Front Pharmacol 2019; 10: 844.
9. Guo XY, Liu J, Liu J, et al. Use of Traditional Chinese Medicine in Chinese patients with coronary heart disease. Biomed Environ Sci 2013; 26 : 303-10.
10. Xu DP, Wu HL, Lan TH, et al. Effect of Shenzhu Guanxin recipe on patients with angina pectoris after percutaneous coronary intervention: a prospective, randomized controlled trial. Chin J Integr Med 2015; 21: 408-16.
11. Xu DP, Zou DZ, Qiu HL, Wu HL. Traditional Chinese Medicine Shenzhu Guanxin granules mitigate cardiac dysfunction and promote myocardium angiogenesis in myocardial infarction rats by upregulating PECAM-1/CD31 and VEGF expression. Evid Based Complement Alternat Med 2017; 2017: 5261729.
12. Wang X, Ji X. Sample size estimation in clinical research: from randomized controlled trials to observational studies. Chest 2020; 158: S12-20.
13. Go GW. Low-density lipoprotein receptor-related protein 6 (LRP6) is a novel nutritional therapeutic target for hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis. Nutrients 2015; 7: 4453-64.
14. Daskalopoulos EP, Blankesteijn WM. Effect of interventions in WNT signaling on healing of cardiac injury: a systematic review. Cells 2021; 10: 207.
15. Abeyrathna P, Su Y. The critical role of Akt in cardiovascular function. Vascul Pharmacol 2015; 74: 38-48.
16. Ahmad KA, Ze H, Chen J, et al. The protective effects of a novel synthetic β-elemene derivative on human umbilical vein endothelial cells against oxidative stress-induced injury: Involvement of antioxidation and PI3k/Akt/eNOS/NO signaling pathways. Biomed Pharmacother 2018; 106: 1734-41.
17. Foulquier S, Daskalopoulos EP, Lluri G, Hermans KCM, Deb A, Blankesteijn WM. WNT signaling in cardiac and vascular disease. Pharmacol Rev 2018; 70: 68-141.
Options
Outlines

/

〈 〉